• Mashup Score: 0

    The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.

    Tweet Tweets with this article
    • Botensilimab and balstilimab elicited durable responses and provided OS benefits in patients with microsatellite stable mCRC that is resistant to chemotherapy and/or immunotherapy. @myESMO #GI23 #crcsm https://t.co/QNS8qszFoW

  • Mashup Score: 0

    The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.

    Tweet Tweets with this article
    • Data from the non–MSI-H cohort of the phase 1 C-800-01 trial showed that botensilimab plus balstilimab produced a median OS of 20.9 months in patients with chemotherapy- and/or immunotherapy-resistant MSS mCRC. @myESMO #GI23 #crcsm https://t.co/bmtYaJP0XL https://t.co/7eYCl3pmP2

  • Mashup Score: 0

    Daniel Walden, MD, discusses the goal of analyzing RNA expression of wild-type HR genes in CRC, the importance of evaluating the benefit of chemotherapeutic approaches in patients with HRP CRC based on RNA expression levels, and the next steps for validating and implementing these findings in clinical practice.

    Tweet Tweets with this article
    • Low RNA Expression of RAD51, BRCA1 Associated With Prolonged OS in HRP CRC @Gastronc @MayoClinic @ASCO #GI23 #crcsm https://t.co/ESd0i7CmrK

  • Mashup Score: 0

    Investigators are assessing the combination of avelumab and lurbinectedin as maintenance therapy for patients with metastatic urothelial carcinoma who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial.

    Tweet Tweets with this article
    • Investigators are assessing avelumab & lurbinectedin as maintenance therapy for pts w/ mUC who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial. @sonpavde @DanaFarber #GI23 #oncology https://t.co/kkrVcRlHGb https://t.co/q2sLjjgPDK

  • Mashup Score: 0

    Investigators are assessing the combination of avelumab and lurbinectedin as maintenance therapy for patients with metastatic urothelial carcinoma who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial.

    Tweet Tweets with this article
    • Investigators are assessing avelumab & lurbinectedin as maintenance therapy for pts w/ mUC who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial. @sonpavde @DanaFarber #GI23 #oncology https://t.co/O7Kxgty8zl